Please try another search
Period Ending: | 2023 31/12 |
2023 30/09 |
2023 30/06 |
2023 31/03 |
|||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 73822.5 | 67574.41 | 76902.72 | 84717.31 | |||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||
Total Assets | 257818.02 | 264179.97 | 272651.8 | 276540.93 | |||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||
Total Current Liabilities | 57598.93 | 49175.38 | 56283.59 | 57184.92 | |||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||
Total Liabilities | 96859.76 | 88531.97 | 96508.48 | 98586.06 | |||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||
Total Equity | 160958.26 | 175648.01 | 176143.32 | 177954.87 | |||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||
Total Liabilities & Shareholders' Equity | 257818.02 | 264179.97 | 272651.8 | 276540.93 | |||||||||||||||||||||||||||||||||||||||||||||
Total Common Shares Outstanding | 9.98 | 9.98 | 9.96 | 9.98 | |||||||||||||||||||||||||||||||||||||||||||||
Total Preferred Shares Outstanding | - | - | - | - |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on the balance sheet, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review